Literature DB >> 476124

Post-proline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man.

T Yoshimoto, K Ogita, R Walter, M Koida, D Tsuru.   

Abstract

Synthesis and application of the first fluorogenic substrate, N-carbobenzoxyglycylprolyl-4-methylcoumarinyl amide (Z-Gly-Pro-MeCouNH) for the determination of the post-proline cleaving enzyme (EC 3.4.21.-) were reported. Maximal activity of the enzyme purified from lamb kidney for the new substrate was observed at pH 7.0. This substrate showed a higher affinity (Km = 0.02 mM) for the enzyme than the proline containing substrates studied previously and allowed the detection of 10-50 ng post-proline cleaving enzyme activity per ml sample after a 1 min incubation period. Distribution of post-proline cleaving enzyme and other proline specific peptidases in rat tissues was studied using Z-Gly-Pro-MeCouNH and other proline-containing substrates. High post-proline cleaving enzyme activity was observed in testis, liver and skeletal muscle. Inhibition experiments indicated that post-proline cleaving enzyme activity was completely inactivated by 0.1 mM diisopropylphosphofluoridate and Z-Gly-Pro-chloromethylketone, as had been found in the case of the enzyme isolated from lamb kidney. Activity in human body fluids was also tested for levels of post-proline cleaving enzyme activity using Z-Gly-Pro-MeCouNH and semen was found to show the highest cleaving activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476124     DOI: 10.1016/0005-2744(79)90053-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

1.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.

Authors:  K Toide; T Fujiwara; Y Iwamoto; M Shinoda; K Okamiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

2.  The activities of six exo-and endopeptidases in the substantia nigra, neostriatum, and cortex of the rat brain.

Authors:  M E Gallegos; M M Zannatha; E G Osornio; A S Sánchez; F A Posadas del rio
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

3.  Prolyl endopeptidase catalysis. A physical rather than a chemical step is rate-limiting.

Authors:  L Polgár
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

4.  Effect of ZTTA, a prolyl endopeptidase inhibitor, on memory impairment in a passive avoidance test of rats with basal forebrain lesions.

Authors:  Y Shishido; M Furushiro; S Tanabe; A Taniguchi; S Hashimoto; T Yokokura; S Shibata; T Yamamoto; S Watanabe
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

5.  Rapid purification of proline-specific endopeptidase fromFlavobacterium meningosepticum heterologously expressed inEscherichia coli.

Authors:  T Diefenthal; H Dargatz
Journal:  World J Microbiol Biotechnol       Date:  1995-03       Impact factor: 3.312

6.  Dipeptidyl peptidase IV in mammalian lungs.

Authors:  E Krepela; J Viccar; L Zizková; E Kasafírek; Z Kolár; V Lichnovský
Journal:  Lung       Date:  1985       Impact factor: 2.584

7.  Evidence for pyroglutamyl peptidase I and prolyl endopeptidase activities in the rat insulinoma cell line RINm 5F: lack of relationship with TRH metabolism.

Authors:  P Salers; L H Ouafik; P Giraud; A Dutour; J Y Maltese; C Oliver
Journal:  Mol Cell Biochem       Date:  1991-07-24       Impact factor: 3.396

8.  Inhibitors of prolyl endopeptidase: characterization of the pharmacophoric pattern using conformational analysis and 3D-QSAR.

Authors:  T Langer; C G Wermuth
Journal:  J Comput Aided Mol Des       Date:  1993-06       Impact factor: 3.686

9.  An improved noninfectious murine skin model of organized granulomatous inflammation.

Authors:  T Iida; Y Nozaki; K Fukuyama; W L Epstein
Journal:  Experientia       Date:  1991-03-15

10.  Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum.

Authors:  M F Powell; T Stewart; L Otvos; L Urge; F C Gaeta; A Sette; T Arrhenius; D Thomson; K Soda; S M Colon
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.